hydrophobic interface with 14-3-3 proteins, and we show that 14-3-3 activates these toxins independent of their phosphopeptide groove binding C-termini, by preventing their aggregation.
shaped 14-3-3 dimer. 17 By contrast, the interaction of ExoS with 14-3-3 proteins is phosphorylation independent, although it is mediated by a C-terminal segment of ExoS binding in the same groove. [19] [20] [21] Previous work has clarified the importance of the hydrophobic side chains in a short sequence motif, 426 LDLA 429 in ExoS, in the interaction with 14-3-3 proteins and in Pseudomonas virulence. [22] [23] [24] This motif (hereafter designated LDLAbox) is conserved in ExoT as well as in the putative 14-3-3 activated bacterial orthologues, AexT 25 and VopT. 26 The extended LDLA-box has also been used as template for synthetic ExoS inhibitory peptides. 27, 28 But whether and how 14-3-3 binding to this short hydrophobic sequence is connected to the catalytic activity of the toxins is unknown.
We determined crystal structures of human 14-3-3 in complex with the ART domain of both ExoS and ExoT. This identified an extensive novel binding interface. ExoS constructs terminating at S419, and thus lacking the LDLA-box, bound 14-3-3 with sub-micromolar affinity; they were inactive when the complex was reconstituted, but had bona fide ExoS activity when co-expressed with 14-3-3. We concluded that the core of the ExoS ART domain is competent for catalysis. This was supported by swapping the ExoS C-terminal segment including the LDLA-box with the C-terminal fragment of the 14-3-3 independent toxin Vis from Vibrio splendidus. The resulting chimeric toxin has ADP-ribosyltransferase activity toward ExoS targets in the absence of 14-3-3. Recombinant ExoS was prone to aggregation, and 14-3-3 stabilized ExoS during thermal aggregation. Collectively, our results indicate that 14-3-3 proteins act as exotoxin chaperones rather than activators.
Results
Crystal structures of the ExoS:14-3-3 and ExoT:14-3-3 complexes ADP-ribosyltransferase activity of ExoS and ExoT requires 14-3-3 binding, but the mechanism of activation was unknown, and no structural models were available for any 14-3-3 activated toxin. We addressed these problems by X-ray crystallography and biochemical analyses. To identify suitable combinations of exotoxin ART domains and 14-3-3 isoforms to study, we evaluated 14-3-3 concentration dependent exotoxin activities in vitro. Six of the seven human 14-3-3 isoforms stimulated ExoS enzymatic activity to similar extent; 14-3-3 had markedly lower apparent affinity; and 14-3-3 was the isoform with the highest apparent affinity for the toxin (Supplementary Fig. 1) . We co-expressed 14-3-3 with either ExoS E379A,E381A or ExoT wt ART domains in Escherichia coli ( Fig. 1a; for details, see the Supplementary Methods section). Using immobilized metal ion chromatography we isolated hexahistidine-tagged ADP-ribosyltransferase domains of either toxin -ExoS 233-453(E379A, E381A) and ExoT 235-435(wt) -in complex with untagged 14-3-3. For both exotoxins, ion exchange chromatography on heparin sepharose, as well as consecutive size exclusion chromatography coupled to right-angle light scattering (SEC-RALS), indicated the formation of protein complexes of various constitutions. A protein complex with an apparent molecular weight of roughly 83.5 kDa (indicative of a "heterotrimer": an ExoS E379A,E381A monomer bound to a 14-3-3 dimer; expected molecular weight 83246 Da; Fig. 1b ) readily crystallized under various conditions. We obtained crystals in space group C2 that diffracted to 3.24 Å and contained one heterotrimer in the asymmetric unit. We solved the structure using molecular replacement with 14-3-3 and Vis toxin (PDB entries 2c23 21 and 4xzj 29 ) as search models ( Fig. 1c and Table 1 ). A complex with an apparent molecular weight of roughly 95 kDa ("heterotetramer"; expected molecular weight 104206 Da; Fig. 1d ) yielded crystals of space group P2 1 2 1 2 that diffracted to 3.24 Å (Fig. 1e) . Subsequent work (see Supplementary Methods for details) resulted in crystal structures of the 14-3-3:ExoS apo heterotrimer at 2.34 Å, the heterotrimer with the non-hydrolyzable NAD + analog, carba-NAD in the active site at 2.50 Å ( Fig. 1f,g) , and the heterotrimer with inhibitor STO1101 30 at 3.24 Å resolution ( Supplementary Fig. 2 ). The 14-3-3:ExoT complexes showed a similar distribution of various molecular weight species (Supplementary Figs. 3,4) . We determined the structure of the 14-3-3:ExoT heterotetramer in complex with STO1101, however the model could not be refined beyond ~3.80 Å resolution. The 14-3-3 complexes of ExoS and ExoT looked very similar overall ( Supplementary Fig. 5 ), and the STO1101-bound ART domains alone (C chains) aligned with a root mean square deviation (RMSD) of 0.97 Å. 31
Figure 1
Crystal structures of 14-3-3:ExoS and 14-3-3:ExoT complexes. (a) Schematic representation of co-expression constructs used for structure determination. Triangles represent the E379A,E381A double mutation. (b,d) SEC-RALS profiles of the heterotrimeric (c) and heterotetrameric (d) 14-3-3:ExoS complexes (main peaks). Estimated molecular weights are indicated. (c,e) Structures of the 14-3-3:ExoS heterotrimer (c) and heterotetramer (e). The 14-3-3 dimer is shown in gray. Numbers in italics indicate the ExoS residues that were resolved in the electron density. (f) Detail of the electron density around carba-NAD in the active site of ExoS (2F obs -F calc electron density map contoured at 1σ (0.1073 eÅ -3 )). (g) Comparison of the ExoS apo and carba-NAD structures. The loop containing F354 is in two different conformations, where the open conformation from the apo structure is marked with an asterisk. Secondary structural elements are numbered. (h) Structure of the 14-3-3:ExoT heterotetramer. (c,e,g,h) ExoS respectively ExoT are shown colored in a gradient from the N-terminus (blue) to the C-terminus (red) of the construct.
A novel interface between 14-3-3 and the Pseudomonas ART exotoxins
Our crystal structures revealed an extensive novel interface between 14-3-3 and the ExoS and ExoT ART domains. This site involves the C-terminal -helices-8 and -9 of 14-3-3, and can be sub-divided into two parts: (i) The two proteins bury a common hydrophobic core made up of side chains originating from the 14-3-3 C-terminal helices and the central sheet of ExoS/T (primarily strands 4, 7 and 8; Fig. 2a-c) . This sub-site constitutes roughly half of the total contact area between the two proteins (ExoS: 762 Å 2 out of 1580 Å 2 ; ExoT: 766 Å 2 out of 1582 Å 2 ). 32 (ii) The short segment that connects the LDLA-box containing exotoxin helix 7 with the core of the ART domain forms an extensive network of hydrogen bonds with the turn between 14-3-3 helices 8 and 9 (not shown). The entire interface between 14-3-3 and the ART domain is similar in ExoS and ExoT (Supplementary Fig. 5 ) and, based on protein sequence comparison, appears to be well conserved in other 14-3-3 dependent toxins ( Supplementary Fig. 6 ).
This novel interface between the exotoxins and 14-3-3 proteins might be a useful target for development of ExoS and ExoT inhibitors. Fortuitously, one of only few potential protein protein interaction (PPI) inhibitors known to bind 14-3-3 outside of the amphipathic groove, the compound NV-1, was shown to bind at the rim of the new ExoS/T binding site ( Fig. 2c) . 33 We found that STO1704, a compound related to NV-1, inhibited K-Ras modification by ExoS 233-453 and CRK modification by ExoT 235-457 in a dose dependent manner ( Fig. 2d and Supplementary Fig. 7) . The potency is low (IC 50 638 and 726 M, respectively); nevertheless this provides proof-of-principle in support of PPI inhibitors as ExoS/T inhibitors.
Our crystal structures of the 14-3-3:ExoS and the 14-3-3:ExoT ART domain complexes all revealed the bowl-shaped 14-3-3 dimer that aligned well with many previous structures of 14-3-3 isoforms (root mean square deviations of less than 1 Å over approximately 230 Cpairs). Neither the 14-3-3 dimer nor the toxin-bound 14-3-3 protomer show any significant conformational differences compared to the previous ExoS peptide bound structures. 21, 23 Thus our structures show that the LDLA-box in the context of the ART domain binds to 14-3-3 as the LDLA-box containing peptides, and in binding, does not distort the 14-3-3 structure: The ART domain and its C-terminal extension appear to wrap onto the solid scaffold of the 14-3-3 dimer. Fig. 1c ) was rotated to the left and then down toward the viewer. Main panel: Sidechains of each protein that participate in interactions are shown (gold, ExoS; grey, 14-3-3) and hydrogen bonds are indicated as dots. The binding site for PPI inhibitor NV1 33 is indicated by the NV1 structure (carbons in cyan). (d) Concentration dependent inhibition of ExoS K-Ras modification, and ExoT Crk modification, by the NV1 analog, STO1704. The chemical structure of STO1704 is shown.
A second LDLA-box binds the second 14-3-3 protomer in the heterotrimeric complex
In all our protein complex structures, the phosphoprotein binding site of the exotoxin bound 14-3-3 protomer was occupied by a peptide containing the LDLA-box in a short -helical segment (ExoS residues 420 QGLLDALDLAS 430 ; Fig. 3a ) in which the D427 side chain hydrogen bonded with the 14-3-3 Y127 and Y130 side chains, and the hydrophobic side chains formed hydrophobic interactions within the amphipathic groove of 14-3-3 ( Fig. 3b) . Both positioning and interaction pattern were virtually identical in previous crystal structures of ExoS derived peptides in complex with 14-3-3 proteins. 21, 23 
Figure 3
A second LDLA-box is capable of binding the second 14-3-3 protomer. (a) Sequence alignment of 14-3-3 dependent toxins ExoS, ExoT, AexT, and VopT and, for comparison, the 14-3-3 independent Vis toxin. Presence of LDLA-box 1 (green arrowheads) unites all 14-3-3 dependent toxins; several also feature a second LDLA-box (orange arrowheads) at their very C-terminus. (b) ExoS LDLA-box 1 binding to the amphipathic groove of 14-3-3 and comparison to phosphopeptide binding at the same site (PDB entry 4o46). (c) ExoS LDLA-box 1 and -2 binding to the two 14-3-3 protomers. (d) Anisotropy of GFP-tagged ExoS constructs indicated tight binding of the ExoS ART domain (residues 233-453) to 14-3-3. Truncation of LDLA-box 2 (residues 233-435) led to a slight reduction in apparent affinity. Truncation of both LDLA-boxes resulted in a protein (residues 233-419) that bound 14-3-3 with sub-micromolar affinity using only the novel binding site ( Fig. 2) . (e) Yeast toxicity assay of ExoS. Five-fold serial dilutions of yeast cells spotted on agar containing either glucose (target gene expression repressed) or galactose/raffinose (expression induced). Expression of the ExoS ADP-ribosyltransferase domain is highly toxic, unless the C-terminal segment ExoS 420-453 , containing both LDLA-boxes, is absent.
ExoS, ExoT and AexT of the 14-3-3 dependent ADP-ribosylating toxins contain a second LDLA motif (ExoS residues 450-453; designated LDLA-box 2) in their very C-termini ( Fig. 3a and Supplementary Fig. 6 ). In one of our crystal structures of the 14-3-3:ExoS heterotrimer, the residues connecting LDLA-box 1 and -2, E433 -D442, could not be modelled; but we found unambiguous electron density placing LDLA-box 2 in the phosphoprotein binding site of the second 14-3-3 monomer ( Fig. 1c and 3c) . LDLA-box 2 bound in a configuration that was highly similar to the configuration of LDLA-box 1 in all four structures. This finding prompted us to examine the contribution of LDLA-box 2 to 14-3-3 binding. We used fluorescence anisotropy to estimate the affinities of 14-3-3 to N-terminal GFP fusions of ExoS (containing only LDLA-box 1) and ExoS 233-453 (containing both LDLA-box 1 and -2, and the native C-terminus). The results indicate comparable affinities in the nanomolar range (~40 nM for GFP-ExoS 233-453 ; ~70 nM for GFP-ExoS 233-435 ; Fig. 3d and Supplementary Fig. 8 ). These results were substantiated by in vivo toxicity assays using S.cerevisiae. The yeast has two orthologs of 14-3-3 proteins, Bmh1 and Bmh2, and the side chains contributing to the ExoS interactions in our crystal structures are largely conserved in both. Galactose-induced expression of either ExoS 233-435 or ExoS 233-453 conferred toxicity such that no colonies were formed on galactose containing agar plates ( Fig. 3e) . Conversely, expression of ExoS (lacking both LDLA-boxes) had no effect on colony formation compared to presence of the empty vector. We concluded that LDLA-box 2 binding to the second 14-3-3 protomer was an intriguing observation with possible implications for ExoS regulation. It is conceivable that LDLA-box 2 might participate in the formation of higher molecular weight 14-3-3:exotoxin complexes ( Supplementary Fig. 3 ), or fold onto the ART domain. If such an event was coupled to catalytic activity, it could provide a layer of regulation; possibly, multimerization acts as a sensor for the presence of high amounts of exotoxin, i.e. conditions under which heterotetramer formation would liberate LDLA-box 2 from its binding site.
Mechanism of toxin activation
The importance of LDLA-box 1 binding to the amphipathic groove of 14-3-3 is undisputed, [22] [23] [24] but its role has been unknown. Given the general sequence homology between these exotoxins and ADP-ribosylating toxins of known structure, we initially expected that 14-3-3 binding might unlock an active exotoxin conformation by sequestering the LDLA-box containing C-terminus. However, we could not reconcile the importance of LDLA-box 1 with our crystal structures. Site directed mutagenesis did not support a role for a structural link between 14-3-3 and the NAD + binding site in regulation of catalytic activity ( Supplementary   Fig. 9 and Supplementary Table 2 ). Therefore, we asked whether the putative activating role of 14-3-3 could be substituted by the short carboxy-terminal sequence of a 14-3-3 independent but otherwise homologous toxin. Based on available crystal structures, we designed a chimeric toxin that comprised ExoS residues 233-409, followed by the C-terminus (residues 218-249) 34 of Vis toxin (Fig. 4a) . This construct, designated SxVis, displayed NAD + glycohydrolase activity and ADP-ribosylated K-Ras in the absence of 14-3-3 ( Fig. 4b) . Neither of these activities could be further stimulated by 14-3-3. ExoS alone had no activity without 14-3-3 present (Fig. 4c) . Although SxVis catalytic efficiency (k cat /K M ) of K-Ras modification was >40-fold lower than that of 14-3-3 activated ExoS, SxVis had a K M NAD in the same range as ExoS ( Fig. 4c and Table 2 ) indicating a fully functional active site. These kinetics also indicate that LDLA-box 1 is involved in either target protein recognition or catalysis, but not NAD + binding. Table 2 . (i) ExoS 233-453 in presence of 14-3-3 at varying molar ratio (0 -2, as indicated) was heated at 0.4 K/min while light scattering was measured using a DLS detector. Inset: Half-temperatures of aggregation as a function of [14-3-3] added. 14-3-3 stabilizes ExoS 233-453 against heat induced aggregation. (j) Model of ExoS activation. ExoS has the intrinsic requirements for ADP-ribosyltransferase activity, but is aggregation prone. Aggregation is reversible as long as the LDLA-boxes are accessible to initiate 14-3-3 mediated de-aggregation. Aggregation is prevented by co-expression with 14-3-3, irrespective of the presence of the LDLA-boxes.
These findings, in combination with the observation (Fig. 3d ) that 14-3-3 had considerable affinity for ExoS 233-419 (lacking both LDLA-boxes; Fig. 4d ) prompted us to co-express ExoS 233-419 with 14-3-3. We found that expression of this protein complex elicited toxicity in E.coli, and this toxicity was dependent on the presence of the catalytic glutamates (Fig. 4e) . This was in line with our initial observation that expression of complex containing the full wild type ART domain was toxic. However, we could identify conditions under which protein complex could be produced (Methods). We found that the native complex of ExoS 233-419 and 14-3-3, when purified from cells co-expressing the proteins, ADP-ribosylated K-Ras and had NAD + glycohydrolases activity, whereas the reconstituted complex was inactive ( Fig. 4f,g,h and Supplementary Fig. 10-13) . These findings suggested that LDLA-box 1 is dispensable for ExoS activity, but is needed for other reasons. Since bacterial expression of all exotoxin constructs induced the formation of inclusion bodies, we studied the effect of 14-3-3 on ExoS stability. Using dynamic light scattering, we observed that ExoS 233-453 formed aggregates, with an onset temperature of 46.7 °C ( Supplementary Table 3 ). Substoichiometric amounts of 14-3-3 were able to elevate the transition temperature of ExoS aggregation (Fig. 4i) . The stabilizing effect of 14-3-3 was abrogated by the PPI inhibitor STO1704, whereas carbonic anhydrase, an unrelated protein, had no effect on ExoS aggregation ( Supplementary Table 3 and Supplementary Fig. 14) . Together, this leads us to conclude that 14-3-3 activation of ExoS does not involve a structural transition to enable substrate or target binding, but rather, is a consequence of chaperoning hydrophobic surfaces to prevent the ART domain from aggregating (Fig. 4j) .
Discussion

Mechanism of exotoxin activation
While it is well documented that LDLA-box 1 is crucial for exotoxin activity in vivo, we showed here that the ExoS ART domain is intrinsically active, and that LDLA-box 1 is dispensable for 14-3-3 mediated exotoxin activity in vitro. Our results also indicate that the novel 14-3-3 binding site in the exotoxins is an aggregation prone surface that needs chaperoning. Thus we might assume that in vivo, the exotoxin C-terminus recruits 14-3-3 proteins early during passage through the type 3 secretion system and thereby ensures fast binding of the hydrophobic surface to its chaperone. Some T3SS targets have been shown to traverse the needle complex "head on", starting with the translocation signal containing Nterminus. 35 14-3-3 dependent exotoxins also contain a translocation signal in their Ntermini, 1 but it is unknown whether they enter host cells starting with their N-or their Cterminal end.
Co-expression of ExoS 253-419 with 14-3-3 was found to be toxic to bacteria (Fig. 4e) , while overexpression of the same construct was not toxic to yeast (Fig. 3e) . Although the exotoxin interacting residues appear to be conserved in the yeast 14-3-3 orthologs, it is feasible that the short constructs binds these proteins with lower affinity than human 14-3-3 proteins.
However, the two experimental systems are sufficiently different to exclude a straightforward conclusion regarding the lack of yeast toxicity of this ExoS construct.
Novel binding site
The main contact site between 14-3-3 and the ART domains overlaps with the newly discovered binding interface between the yeast 14-3-3 ortholog, Bmh1, and trehalase. 36 The modes of interaction are different however, as an -helical segment (S722-G729) of trehalase resides in the hydrophobic groove formed by Bmh1 helices-8 and -9 roughly perpendicular to the orientation of the ExoS/T -strands in our complexes. Structures of other complexes of 14-3-3 with client proteins have been determined as well, 37-39 but the binding sites for these proteins show only minor overlap with the ExoS/T binding site ( Supplementary Fig. 12) . In a development of pharmacological interventions involving the novel exotoxin binding site, it will be important to address the question of whether other proteins interact at this site.
Substrate recognition site
Barbieri and coworkers defined a "region A" (ExoT 246-264 ) near the N-terminus of the domain as critical for substrate recognition by ExoT. 40 Our crystal structures show that regions A of both ExoS and -T fold into two helices (1 and 2), unlike the corresponding region with low homology in related toxins (Supplementary Fig. 16 ). We noted differential effects of our F327R mutant depending on whether a proteinaceous substrate or a free arginine analog was available (Supplementary Table 2 ). As 1 and 2 locate close to the NAD + containing active site loop, it is plausible that target protein binding at this site would influence the affinity of ExoS for NAD + .
Future perspectives
Our crystal structures provide important information for a better understanding of 14-3-3 dependent toxins, and also for the development of enzyme inhibitors as potential antiinfectives. However, our discoveries of an exotoxin chaperone function of 14-3-3, of the novel interaction site between the proteins, and of the inhibitory effect of STO1704, encourage development of specific PPI inhibitors of 14-3-3 dependent exotoxin activation. This is especially important as compounds binding to an exotoxin specific site would circumvent the off-target effects expected of inhibitors that bind in the amphipathic groove of 14-3-3 proteins. 41 
Methods
Materials -Fine chemicals and growth media were purchased from SigmaAldrich. 1,N 6fluoresceinyl-NAD + (fluo-NAD + ) was obtained from BioLog, and 1,N 6 -etheno-AMP from Jena
Bioscience. The non-hydrolyzable NAD analog carbanicotinamide adenine dinucleotide (carba-NAD; PubChem ID 112345-60-5) was synthesized as described before, 44 with minor modifications. 1 H-and 13 C-NMR spectra (Supplementary Fig. 17 ) were in agreement with the original report. ExoS/T inhibitor STO1101 (3-(4-oxo-3,5,6,7-tetrahydro-4Hcyclopenta [4, 5] monomers and one ExoS molecule. The structure was solved by molecular replacement using PDB entries 2c23 (14-3-3) and 4xzj (Vis toxin) as search model. 21, 29 The resulting structure ( Supplementary Table 1 ) served as molecular replacement template for all following datasets.
Diffraction data were indexed, integrated using XDS, 48 scaled and truncated using SCALA 49 or XSCALE and the CCP4 suite of programs. BESSY synchrotron diffraction data were processed using XDSAPP. 47 The structures were solved by molecular replacement with PHASER. 50 All structures were refined using phenix.refine 51 or Buster, 52 and model building was done with
Coot. 53 Analysis of the structure showed a crystal packing that allowed the 14-3-3 C-terminus to insert in the active site of ExoS in a neighbor unit cell ( Supplementary Fig. 3g,h) . We redesigned the co-expression vector, substituting the full length 14-3-3 cDNA with a cDNA coding for a construct truncated after N234. The resulting protein complex yielded crystals in space group C2 that diffracted to 2.34 Å (apo form) and that could be used to determine structures of ligand complexes after soaking ( Table 1) . where r is the anisotropy of the population of GFP-ExoS in solution, r 0 is the initial anisotropy (in the absence of 14-3-3, r ∞ is the anisotropy of GFP-ExoS at saturating [14-3-3], P T is the total [14-3-3], L T is the total GFP-ExoS, and K d,app is the apparent binding affinity of GFP-ExoS for 14-3-3.
Enzymatic analyses -General
Thermal aggregation assay by dynamic light scattering (DLS) -ExoS 233-453 (10 μM) and 14-3-3β (variable) were pre-incubated in 20 mM HEPES, 300 mM NaCl, 10% Glycerol, 1 mM TCEP, pH 7.5. Samples were cleared of aggregates in a table top centrifuge (17500 x g; 30 min, 4 °C). DLS analyses were performed on 50 μl of the supernatant in a quartz cuvette using a detector at 90 degrees from the incident laserbeam in a Zetasizer μV instrument (Malvern).
Protein stability was assessed using a temperature gradient from 25 to 70°C. Z-average size was plotted against temperature and the aggregation onset temperature was determined by extrapolating the linear section of the transition, at its highest slope, backward to its intersection with the baseline at low temperatures.
Assay of protein toxicity in yeast -ExoS 233-419 , ExoS 233-435 , ExoS 233-453 sequences were amplified by PCR and integrated downstream the galactose-inducible GAL1-10 promoter in the yeast integrative plasmid vector YIplac211. Correct integration was controlled by DNA sequencing. Plasmids were linearized using the StuI restriction enzyme (Roche), and integrated at the URA3 locus in the budding yeast Saccharomyces cerevisiae W303 using lithium acetate-mediated transformation. 54 The genotypes of the resulting strains are listed
in Supplementary Table 4 . To evaluate the viability of yeast strains expressing the different ExoS variants, a volume equivalent to OD 600 = 3 of mid-log phase cells grown in YEP media supplemented with 2% glucose were harvested using centrifugation. Resulting cell pellets were resuspended in 1 ml sterile water, and 3 µl of 5-fold serial dilutions were spotted on YEP plates supplemented with 2% glucose (expression "off"), or with 2% raffinose and 2% galactose (expression "on"). Images shown in Fig. 3e were taken after 24 h incubation at 30°C.
Assay of protein toxicity in E.coli -Cells of strain T7Express lysY (New England Biolabs) were transformed with expression plasmids and grown on agar overnight. Liquid cultures (Lucia Broth) were prepared and allowed to grow at 37°C to saturation. New liquid cultures (Terrific Broth) were inoculated and allowed to grow at 37°C to OD 600 of 1.0 -1.2. Cultures were diluted to OD 600 of 0.1 using either Terrific Broth or Terrific Broth supplemented with 1 mM IPTG. Serial dilutions were prepared of which 10 μl were spotted on either agar or agar supplemented with 1 mM IPTG. Plates were imaged after overnight incubation at 37°C.
